The global multiple system atrophy (MSA) market is estimated to garner a sizeable revenue by growing at a notable CAGR over the forecast period, i.e., 2022 – 2030. The growth of the market can be attributed to the growing occurrence of multiple system atrophy across the world, significant shift in people’s lifestyles globally, and rising consumption of alcohol and narcotics. As per the data provided by the Rare Diseases organization, the incidence of multiple system atrophy in the United States alone is 0.6 cases per 100,000 people every year. An estimated 1,900 new cases of the disease occur each year in the country. In addition to these, increasing research and development activities to develop an effective treatment for systemic atrophies and rise in healthcare expenditure in developed and developing nations are also expected to drive growth for the market in the upcoming years. Furthermore, high exposure of people to environmental toxins is projected to offer ample growth opportunities to the market in the near future.
The market is segmented by diagnosis into magnetic resonance imaging (MRI), positron emission tomography (PET), single photon emission computed tomography (SPECT), tilt table test, and others, out of which, the magnetic resonance imaging (MRI) segment is anticipated to hold the largest share in the global multiple system atrophy (MSA) market on account of the high usage of MRI techniques for differentiation of systemic atrophy with Parkinson’s disease, and its usefulness in tracking the progression of multiple system atrophy. Along with this, the segment for tilt table test is also predicted to occupy a significant market share during the forecast period owing to the rising use of this test to document the extent of blood pressure irregularities, which is fundamental for diagnosing systemic atrophies. CLICK TO DOWNLOAD SAMPLE REPORT
According to the statistics by the World Health Organization, the global per capita healthcare expenditure amounted to USD 1,064.741 in the year 2017. The worldwide healthcare expenditure per person grew from USD 864.313 in 2008 to USD 1,110.841 in 2018, where the U.S. is the top country that amounted to healthcare expenditure of USD 10, 623.85 per capita in 2018. As of 2018, the domestic general government healthcare spending in the U.S. was USD 5355.79, which grew from USD 3515.82 in 2008. These are some of the factors responsible for market growth over the past few years. Moreover, as per the projections by the Centers for Medicare & Medicaid Services (CMS), the estimated average annual percent change related to National Health Expenditures (NHE) in the U.S. was 5.2% in 2020 as compared to 2019 (4.5%). Furthermore, the National Health Expenditures are projected to reach USD 6,192.5 Billion in 2028, where the per capita expenditure is estimated to touch USD 17,611 in the same year. These are notable indicators that are anticipated to create lucrative business opportunities in upcoming years.
On the basis of geographical analysis, the global multiple system atrophy (MSA) market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and the Middle East & Africa region. The market in the Asia Pacific is estimated to witness noteworthy growth over the forecast period on the back of the increasing number of cases of multiple system atrophy, especially in Japan, high patient pool and growing government initiatives to improve the infrastructure of healthcare in the region. Moreover, the market in North America is expected to gather the largest share during the forecast period, which can be credited to the rising prevalence of neurological disorders, increasing healthcare spending, well established healthcare infrastructure, and strong presence of prominent market players in the region. According to the Centers for Medicare and Medicaid Services, U.S. health care spending grew 4.6 percent in 2019, reaching $3.8 trillion or $11,582 per person. The health spending accounted for 17.7 percent of the country’s total GDP share.
The global multiple system atrophy (MSA) market is further classified on the basis of region as follows:
Our in-depth analysis of the global multiple system atrophy (MSA) market includes the following segments:
FREQUENTLY ASKED QUESTIONS
The major growth drivers for the market are growing occurrence of multiple system atrophy across the world and increasing research and development activities to develop effective treatment for systemic atrophies.
The market is anticipated to attain a notable CAGR over the forecast period, i.e., 2022 – 2030.
Lack of awareness about the disease in lower economic regions is estimated to hamper the market growth.
Asia Pacific will provide more business opportunities for market growth owing to the increasing number of cases of multiple system atrophy, and high patient pool of the region.
The major players in the market are Chelsea Therapeutics International, Ltd., Biohaven Pharmaceuticals, Inc., Sumitomo Dainippon Pharma Co., Ltd., AstraZeneca plc, and others.
The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.
The market is segmented by type, diagnosis, and by region.
The MRI segment is anticipated to hold largest market size and is estimated to grow at a robust CAGR over the forecast period and display significant growth opportunities.
Select License Type
Direct access to analyst to help you understand the market in a better way to handle your critical question
Citing your business specific requirement our consultant would assist you ensuring targeted goal is achieved
Get 10% free customization